Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl

Molecular Pharmacology

Volumn 68, Issue 5, 2005, Pages 1408-1414

  Andoh, Tsugunobu ^a,c   Boon Chock, P ^a   Murphy, Dennis L ^b   Chiueh, Chuang C ^d  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF TOYAMA   (Japan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; 1 METHYL 4 PHENYLPYRIDINIUM; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; OLIGONUCLEOTIDE; PROTEIN BCL 2; SELEGILINE; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE INDUCTION; HUMAN; HUMAN CELL; MESENCEPHALON; MOUSE; NERVE CELL CULTURE; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOPROTECTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIPID PEROXIDATION; MICE; PHOSPHORYLATION; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SELEGILINE; THIOREDOXIN;

EID: 27544468505     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.012302     Document Type: Article

References (40)

1. Abate C, Patel L, Rauscher FJ 3rd, and Curran T (1990) Redox regulation of fos and jun DNA-binding activity in vitro. Science (Wash DC) 249:1157-1161.
2. Andoh T, Chiueh CC, and Chock PB (2003) Cyclic GMP-dependent protein kinase regulates the expression of thioredoxin and thioredoxin peroxidase-1 during hormesis in response to oxidative stress-induced apoptosis. J Biol Chem 278:885-890.
3. Andoh T, Chock PB, and Chiueh CC (2002a) Preconditioning-mediated neuroprotection: role of nitric oxide, cGMP and new protein expression. Ann NY Acad Sci 962:1-7.
4. Andoh T, Chock PB, and Chiueh CC (2002b) The roles of thioredoxin in protection against oxidative stress-induced apoptosis in SH-SY5Y cells. J Biol Chem 277:9655-9660.
5. Andrews AM, Ladenheim B, Epstein CJ, Cadet JL, and Murphy DL (1996) Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2′-NH2-MPTP on serotonergic and noradrenergic nerve terminals. Mol Pharmacol 50:1511-1519.
6. Bai J, Nakamura H, Hattori I, Tanito M, and Yodoi J (2002) Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells. Neurosci Lett 321:81-84.
7. Birkmayer W, Knoll J, Riederer P, and Youdim MB (1983) (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 19:170-176.
8. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, and Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546-4550.
9. Carrillo MC, Kanai S, Nokubo M, and Kitani K (1991) (-)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48:517-521.
10. Chiueh CC (1988) Dopamine in the extrapyramidal motor function. A study based upon the MPTP-induced primate model of parkinsonism. Ann NY Acad Sci 515:226-238.
11. Chiueh CC and Andoh T (2002) Cyclic GMP-mediated preconditioning gene induction as a treatment of Alzheimer's dementia and Parkinson's disease, in Mapping the Progress of Alzheimer's and Parkinson's Disease (Mizuno Y, Fisher A, and Hanin I eds), pp 447-454. Advances in Behavioral Biology, Vol. 51. Kluwer Academic/Plenum Publishers, New York.
12. Chiueh CC, Wu RM, Mohanakumar KP, Sternberger LM, Krishna G, Obata T, and Murphy DL (1994) In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann NY Acad Sci 738:25-36.
13. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, and Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106:209-210.
14. Davis RJ (1995) Transcriptional regulation by MAP kinases. Mol Reprod Dev 42:459-467.
15. Ebadi M, Sharma S, Shavali S, and El Refaey H (2002) Neuroprotective actions of selegiline. J Neurosci Res 67:285-289.
16. Gille G, Rausch WD, Hung ST, Moldzio R, Janetzky B, Hundemer HP, Kolter T, and Reichman H (2002) Pergolide protects doperminergic neurons in primary culture under stress condition. J Neural Transm 109:633-643.
17. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC, Heinonen EH, and Lammintausta R (1991) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature (Lond) 311:467-469.
18. Heinonen EH and Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand Suppl 136:44-59.
19. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, and Rhee SG (1998) Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 273:6297-6302.
20. Kitani K, Kanai S, Carrillo MC, and Ivy GO (1994) (-)Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats. Ann NY Acad Sci 717:60-71.
21. Knoll J (2000) (-)Deprenyl (Selegiline): past, present and future. Neurobiology 8:179-199.
22. Kojima S, Matsuki O, Nomura T, Yamaoka K, Takahashi M, and Niki E (1999) Elevation of antioxidant potency in the brain of mice by low-dose γ-ray irradiation and its effect on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced brain damage. Free Radic Biol Med 26:388-395.
23. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (Wash DC) 290:767-773.
24. Kunikowska G, Gallagher I, Glover V, Clow A, and Jenner P (2002) Effects of shortand long-term (-)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain. Brain Res 953:1-11.
25. LeWitt PA (1991) Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta Neurol Scand Suppl 136:79-86.
26. Moskovitz J, Berlett BS, Poston JM, and Stadtman ER (1999) Methionine sulfoxide reductase in antioxidant defense. Methods Enzymol 300:239-244.
27. Murphy DL, Cohen RM, Siever LJ, Roy B, Karoum F, Wyatt RJ, Garrick NA, and Linnoila M (1983) Clinical and laboratory studies with selective monoamineoxidase-inhibiting drugs. Implications for hypothesized neurotransmitter changes associated with depression and antidepressant drug effects. Mod Probl Pharmacopsychiatry 19:287-303.
28. Mytilineou C and Cohen G (1985) Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem 45:1951-1953.
29. Rauhala P, Lin AM, and Chiueh CC (1998) Neuroprotection by S-nitrosoglutathione of brain dopamine neurons from oxidative stress. FASEB J 12:165-173.
30. Revuelta M, Venero JL, Machado A, and Cano J (1997) Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic nigrostriatal system but fails to counteract axotomy- induced degenerative changes. Glia 21:204-216.
31. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO (Eur Mol Biol Organ) J 17:2596-2606.
32. Semkova I, Wolz P, Schilling M, and Krieglstein J (1996) Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol 315:19-30.
33. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, et al. (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51:604-612.
34. Sprague JE and Nichols DE (1995) The monoamine oxidase-B inhibitor l-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 273:667-673.
35. Tariot PN, Sunderland T, Weingartner H, Murphy DL, Welkowitz JA, Thompson K, and Cohen RM (1987) Cognitive effects of l-deprenyl in Alzheimer's disease. Psychopharmacology 91:489-495.
36. Tatton WG, Chalmers-Redman RM, and Tatton NA (2003) Neuroprotection by deprenyl and other propargylamines: glyceraldehydes-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 110:509-515.
37. Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, and Tatton NA (1996) (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 48:45-59.
38. Vizuete ML, Steffen V, Ayala A, Cano J, and Machado A (1993) Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum. Neurosci Lett 152:113-116.
39. + dopaminergic toxicity. J Neural Transm Gen Sect 100:53-61.
40. Yang L, Matthews RT, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney JB Jr, Hyman BT, and Beal MF (1998) 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 18:8145-8152.